Cadence Capital Limited announced its full year results for the financial year ending 30 June 2026, reporting a fund increase of 20.1%, outperforming the All Ordinaries Accumulation Index by 14.4%. The company achieved a profit after tax of $33.4 million, with significant contributions from gold and precious metals stocks. During the year, the company sold down over 80% of its gold and resource stocks due to a decline in gold prices. The share price rose 30.6% over the year, including dividends and franking. Cadence declared a fully franked final dividend of 3.0 cents per share and a special dividend of 1.0 cent per share. The company's profit reserve stands at 25 cents per share, allowing four years of dividends at the current rate, with sufficient franking credits for two years of dividends. The dividend reinvestment plan will remain in operation. The company also recognized opportunities in various quality businesses previously overlooked due to extreme valuations, including CSL, Cochlear, Pro Medicus, and A2 Milk. Cadence continues to focus on market strategies akin to trends observed in the 1970s.
Key Points
Fund increased by 20.1% in FY26.
Outperformed the All Ordinaries Accumulation Index by 14.4%.
Profit after tax was $33.4 million.
Significant contributions from gold and precious metals stocks.
Sold down over 80% of gold and resource stocks.
Share price rose 30.6% over FY26 including dividends and franking.
Declared 3.0 cent fully franked final dividend and 1.0 cent special dividend.
Profit reserve allows for 4 years of dividends at current rates.
Sufficient franking credits for 2 years of dividends.
Dividend reinvestment plan remains in operation.
Identified investment opportunities in CSL, Cochlear, Pro Medicus, A2 Milk.
Focus on market strategies similar to the 1970s trends.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.